Effect of Aldosterone-Producing Adenoma on Endothelial Function and Rho-Associated Kinase Activity in Patients With Primary Aldosteronism
暂无分享,去创建一个
A. Nakashima | N. Kohno | K. Chayama | Y. Kihara | J. Liao | Chikara Goto | Y. Higashi | T. Maruhashi | K. Noma | T. Hidaka | Takeshi Matsumoto | Y. Iwamoto | N. Oda | K. Oki | Yoshiki Aibara | M. Kajikawa | A. Iwamoto
[1] P. Vanhoutte,et al. State of the Art Lecture , 2018, European Psychiatry.
[2] A. Nakashima,et al. Rho-Associated Kinase Activity Is a Predictor of Cardiovascular Outcomes , 2014, Hypertension.
[3] P. Plouin,et al. Cardiovascular Complications Associated With Primary Aldosteronism: A Controlled Cross-Sectional Study , 2013, Hypertension.
[4] A. Nakashima,et al. Nitroglycerine-Induced Vasodilation for Assessment of Vascular Function: A Comparison With Flow-Mediated Vasodilation , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[5] K. Chayama,et al. Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho‐Associated Kinase Activity in Patients With Hypertension , 2012, Clinical pharmacology and therapeutics.
[6] Yukihito Higashi,et al. Rho-Associated Kinase Activity, Endothelial Function, and Cardiovascular Risk Factors , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[7] Katsutoshi Takahashi,et al. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. , 2011, Endocrine journal.
[8] T. Masuyama,et al. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. , 2008, American journal of physiology. Heart and circulatory physiology.
[9] A. Nishiyama,et al. Possible Involvement of Rho-Kinase in Aldosterone-Induced Vascular Smooth Muscle Cell Remodeling , 2008, Hypertension Research.
[10] A. Nishiyama,et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. , 2006, Journal of the American Society of Nephrology : JASN.
[11] T. Tagami,et al. Molecular Mechanism of the Inhibitory Effect of Aldosterone on Endothelial NO Synthase Activity , 2006, Hypertension.
[12] Kunihiro Suzuki,et al. Aldosterone Impairs Vascular Endothelial Cell Function , 2006, Journal of cardiovascular pharmacology.
[13] M. Young,et al. Mechanisms of Mineralocorticoid Action , 2005, Hypertension.
[14] B. Kingwell,et al. Low-Renin Hypertension With Relative Aldosterone Excess Is Associated With Impaired NO-Mediated Vasodilation , 2005, Hypertension.
[15] N. de Las Heras,et al. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. , 2005, Antioxidants & redox signaling.
[16] P. Milliez,et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. , 2005, Journal of the American College of Cardiology.
[17] Maristela L Onozato,et al. Eplerenone Shows Renoprotective Effect by Reducing LOX-1–Mediated Adhesion Molecule, PKC&egr;-MAPK-p90RSK, and Rho-Kinase Pathway , 2005, Hypertension.
[18] A. Zeiher,et al. Endothelial Function: Cardiac Events , 2005, Circulation.
[19] J. Liao,et al. Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[20] A. Struthers,et al. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment , 2004, Heart.
[21] R. Loberg,et al. Rho/Rho Kinase and Phosphoinositide 3-Kinase Are Parallel Pathways in the Development of Spontaneous Arterial Tone in Deoxycorticosterone Acetate-Salt Hypertension , 2004, Journal of Pharmacology and Experimental Therapeutics.
[22] Y. Kanno,et al. Effects of Eplerenone on Heart and Kidney in Two-Kidney, One-Clip Rats , 2004, American Journal of Nephrology.
[23] K. Chayama,et al. Endothelial function and oxidative stress in renovascular hypertension. , 2002, The New England journal of medicine.
[24] K. Chayama,et al. Excess Norepinephrine Impairs Both Endothelium-Dependent and -Independent Vasodilation in Patients With Pheochromocytoma , 2002, Hypertension.
[25] A. Takeshita,et al. Possible Involvement of Rho-Kinase in the Pathogenesis of Hypertension in Humans , 2001, Hypertension.
[26] M. Morissette,et al. Increased Expression and Activity of RhoA Are Associated With Increased DNA Synthesis and Reduced p27Kip1 Expression in the Vasculature of Hypertensive Rats , 2001, Circulation research.
[27] G. Kajiyama,et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. , 2000, Journal of the American College of Cardiology.
[28] G. Kajiyama,et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. , 1999, Circulation.
[29] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[30] A. Hall,et al. Rho GTPases and the actin cytoskeleton. , 1998, Science.
[31] Shuh Narumiya,et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.
[32] K. Kaibuchi,et al. Formation of Actin Stress Fibers and Focal Adhesions Enhanced by Rho-Kinase , 1997, Science.
[33] E. Schiffrin,et al. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. , 1995, Hypertension.
[34] L. Ghiadoni,et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. , 1995, Circulation.
[35] M. Creager,et al. Effect of captopril and enalapril on endothelial function in hypertensive patients. , 1994, Hypertension.
[36] A. Quyyumi,et al. Role of Endothelium‐Derived Nitric Oxide in the Abnormal Endothelium‐Dependent Vascular Relaxation of Patients With Essential Hypertension , 1993, Circulation.
[37] T. Lüscher,et al. Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. , 1990, Hypertension.
[38] A. Quyyumi,et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. , 1990, The New England journal of medicine.
[39] T. Lüscher,et al. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. , 1990, Circulation.
[40] T. Lüscher. Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension? , 1990, American journal of hypertension.
[41] R. Furchgott. Role of endothelium in responses of vascular smooth muscle. , 1983, Circulation research.
[42] N. Zhang. The Diagnosis and Treatment of Primary Aldosteronism , 2011 .
[43] 西坂 麻里. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism , 2008 .
[44] T. Ogihara,et al. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. , 1997, Hypertension.